SAN DIEGO, May 14, 2026 (GLOBE NEWSWIRE) — Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, today reported its first quarter 2026 operating and financial results and reviewed recent business highlights.
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
